Barts Health NHS Trust

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial

Retrieved on: 
Thursday, December 7, 2023
Urea, Quality of life, Protein, Senior lecturer, Hope, Itch, Barts Health NHS Trust, Dry, MD, Therapy, Skin, Dicarboxylic acid, MC2, European, Patient, Safety, Dialysis, CKD, Pharmaceutical industry

CKD-aP Stage 5 (dialysis) and stages 3 and 4 (pre-dialysis), the latter segment having no approved treatment options.

Key Points: 
  • CKD-aP Stage 5 (dialysis) and stages 3 and 4 (pre-dialysis), the latter segment having no approved treatment options.
  • MC2-25 CKD presents a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decades.
  • Jesper L. Lange, CEO of MC2 Therapeutics said: “There is increasing evidence that carbamylation plays a central role in various urea associated skin diseases.
  • This new understanding of the role played by carbamylation in CKD-aP is very exciting and offers hope to millions of patients.”

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial

Retrieved on: 
Thursday, December 7, 2023
Urea, Quality of life, Protein, Senior lecturer, Hope, Itch, Barts Health NHS Trust, Dry, MD, Therapy, Skin, Dicarboxylic acid, MC2, European, Patient, Safety, Dialysis, CKD, Pharmaceutical industry

CKD-aP Stage 5 (dialysis) and stages 3 and 4 (pre-dialysis), the latter segment having no approved treatment options.

Key Points: 
  • CKD-aP Stage 5 (dialysis) and stages 3 and 4 (pre-dialysis), the latter segment having no approved treatment options.
  • MC2-25 CKD presents a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decades.
  • Jesper L. Lange, CEO of MC2 Therapeutics said: “There is increasing evidence that carbamylation plays a central role in various urea associated skin diseases.
  • This new understanding of the role played by carbamylation in CKD-aP is very exciting and offers hope to millions of patients.”

ADVANCING NOVEL CANCER THERAPIES: MOSAIC KEYNOTE PRESENTATION HEADLINES BIO-IT WORLD EUROPE, 29-30 NOVEMBER IN LONDON

Retrieved on: 
Thursday, October 12, 2023
Neoplasm, Senior, Cancer, Partnership, Medicine, Deterministic Barcoding in Tissue for Spatial Omics Sequencing, LDN, Pathology, United Kingdom, Barts Health NHS Trust, Strategic management, Teaching hospital, Consultant, RDN, MOSAIC, Queen Mary University of London, Conference, Research, Medical imaging, Management

LONDON, Oct. 12, 2023 /PRNewswire/ -- A Plenary Keynote address on the first learnings of the $50 million MOSAIC initiative, whose goal is to revolutionize cancer research through spatial omics technologies, will kick off Bio-IT World Conference & Expo Europe, taking place 29-30 November in London.

Key Points: 
  • LONDON, Oct. 12, 2023 /PRNewswire/ -- A Plenary Keynote address on the first learnings of the $50 million MOSAIC initiative, whose goal is to revolutionize cancer research through spatial omics technologies, will kick off Bio-IT World Conference & Expo Europe , taking place 29-30 November in London.
  • This annual gathering fosters collaboration among the United Kingdom's and Europe's medical research, biopharma and technology leaders, who are forging new frontiers in precision medicine together.
  • Spatial omics, combined with AI/ML, will help the partners advance novel therapies for seven difficult-to-treat cancers.
  • "MOSAIC represents the innovations in precision medicine that are only possible when scientific and technology experts collaborate," said Cindy Crowninshield, RDN, LDN, Executive Event Director.

DRIVING PRECISION MEDICINE FORWARD: BIO-IT WORLD EUROPE CONVENES IN LONDON 29-30 NOVEMBER 2023

Retrieved on: 
Thursday, September 21, 2023
Cloud, Partnership, Barts Health NHS Trust, LDN, Data management, Neoplasm, ELIXIR, Biotechnology, Cancer, Biomedical Research, Bioinformatics, Research, RDN, Queen Mary University of London, Government, Organization, Medicine, Drug discovery, Cloud computing, AI, MOSAIC, Conference, FAIR, Pharmaceutical industry

Senior-level scientists and researchers, IT professionals and executives from organizations across life sciences, including pharmaceutical, biotechnology, health systems, academia, government, and national laboratories, will participate in more than 60 sessions in five tracks--R&D in pharma, AI for Pharma, Storage Infrastructure & Cloud Computing, Data Management, and Bioinformatics.

Key Points: 
  • LONDON, Sept. 21, 2023 /PRNewswire/ -- To foster collaboration among the UK and Europe's biopharma and technology leaders who are forging new frontiers in precision medicine, the Bio-IT World Conference & Expo Europe is coming to London 29-30 November 2023.
  • Sessions will showcase the role of AI, FAIR (findable, accessible, interoperable and reusable) data, digital twins, bioinformatics and other technologies in catalyzing progress.
  • Examples include:
    A partnership between Barts Health NHS Trust and Queen Mary University of London, which are investing £600m pounds in a world-leading open-access exascale causal AI computing platform.
  • "Bio-IT World Europe will give participants an exclusive opportunity to network with the people behind the innovations originating in Europe and the UK.

Heimdal Steps Up to Support NHS Trusts Amid Escalating Ransomware Attacks

Retrieved on: 
Thursday, July 27, 2023
Health, Barts Health NHS Trust, NHS, Trust, Trust law, TechCrunch, Pharmaceutical industry

This follows a significant ransomware attack on the UK's largest NHS trust, Barts Health NHS Trust, as reported by TechCrunch.

Key Points: 
  • This follows a significant ransomware attack on the UK's largest NHS trust, Barts Health NHS Trust, as reported by TechCrunch.
  • Ransomware attacks are an escalating concern for public sector organisations, particularly those providing vital services like the NHS.
  • In extending this support, Heimdal looks forward to further strengthening its relationship with NHS Trusts.
  • To benefit from Heimdal's free ransomware protection, NHS Trusts need to register interest on the Heimdal website before August 31st, 2023.

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Retrieved on: 
Thursday, May 18, 2023
New England, National Health Service, Barts Health NHS Trust, Chronic kidney disease, Medicine, Health care, Quality of life, Medication, CSL Vifor, Hemodialysis, Medicines and Healthcare products Regulatory Agency, Patient, Itch, Therapy, CKD, NICE, MHRA, National Institute for Health and Care Excellence, Nursing, Pharmaceutical industry

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis. The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.

Key Points: 
  • The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
  • "The recommendation of Kapruvia® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK," said Fabio Dorigotti, Head Global Medical Affairs of CSL Vifor.
  • "We look forward to continue working with the National Health Service to ensure access to this important medicine for patients as quickly as possible."
  • "Together with VFMCRP, we are committed to bringing our first-of-its kind therapy to providers and patients around the world to help change the way pruritus is managed."

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Retrieved on: 
Thursday, May 18, 2023
New England, National Health Service, Barts Health NHS Trust, Chronic kidney disease, Medicine, Health care, Quality of life, Medication, CSL Vifor, Hemodialysis, Medicines and Healthcare products Regulatory Agency, Patient, Itch, Therapy, CKD, NICE, MHRA, National Institute for Health and Care Excellence, Nursing, Pharmaceutical industry

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis. The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.

Key Points: 
  • The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
  • "The recommendation of Kapruvia® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK," said Fabio Dorigotti, Head Global Medical Affairs of CSL Vifor.
  • "We look forward to continue working with the National Health Service to ensure access to this important medicine for patients as quickly as possible."
  • "Together with VFMCRP, we are committed to bringing our first-of-its kind therapy to providers and patients around the world to help change the way pruritus is managed."

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Retrieved on: 
Thursday, May 18, 2023
New England, National Health Service, Barts Health NHS Trust, Medicine, Health care, Quality of life, CSL Vifor, Hemodialysis, Patient, Therapy, CKD, NICE, MHRA, Pharmaceutical industry

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

Key Points: 
  • ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
  • The decision follows authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
  • “The recommendation of Kapruvia® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK,” said Fabio Dorigotti, Head Global Medical Affairs of CSL Vifor.
  • “We now have an option to help reduce the burden of CKD-related itch.”
    MHRA approval and the NICE recommendation were supported by positive data from two pivotal phase-III trials – KALM-1, conducted in the U.S. (New England Journal of Medicine 2020; 382:222-232), and the global KALM-2, as well as supportive data from an additional 32 clinical studies.

icometrix & Queen Mary University of London receive prestigious AI Award from the National Institute for Health and Care Research (NIHR) to investigate the impact of AI applied to MRI in the care of people with multiple sclerosis (MS)

Retrieved on: 
Friday, March 3, 2023
Queen Mary University of London, Care, Multiple sclerosis, Pressure, Barts Health NHS Trust, Neurology, Quality of life, InHealth Group, Nottingham University Hospitals NHS Trust, MRI, Head, Publication, Radiology, News, Software, University, DMT, Brain, Multiple Sclerosis Society, NHS, Research, MS, PPI, QMUL, Central nervous system, AI, Neuro, Patient, NIHR, Medical imaging, Pharmaceutical industry

LONDON, March 3, 2023 /PRNewswire/ -- icometrix is proud to announce that, together with Queen Mary University of London (QMUL), it has been awarded the prestigious AI Award in Health and Care. This collaborative program will investigate the impact of AI on the assessment of MRI and decision making in the context of multi-disciplinary team meetings for people with MS. It is hoped that this research will lead to better care for people with MS (pwMS).

Key Points: 
  • The programme called AssistMS, is a collaboration between icometrix, QMUL, the University of Nottingham, and Barts Health and Nottingham University Hospitals Trusts.
  • The project is further supported by the East Midlands Imaging Network (EMRAD), InHealth Group and the MS Society of Great Britain & Northern Ireland.
  • pwMS receiving disease-modifying treatments (DMT) undergo annual MRI of the central nervous system to monitor disease activity.
  • Our joint efforts will undoubtedly transform care and improve outcomes for many PwMS for the better across Europe and beyond."

icometrix & Queen Mary University of London receive prestigious AI Award from the National Institute for Health and Care Research (NIHR) to investigate the impact of AI applied to MRI in the care of people with multiple sclerosis (MS)

Retrieved on: 
Friday, March 3, 2023
Queen Mary University of London, Care, Multiple sclerosis, Pressure, Barts Health NHS Trust, Neurology, Quality of life, InHealth Group, Nottingham University Hospitals NHS Trust, MRI, Head, Publication, Radiology, News, Software, University, DMT, Brain, Multiple Sclerosis Society, NHS, Research, MS, PPI, QMUL, Central nervous system, AI, Neuro, Patient, NIHR, Medical imaging, Pharmaceutical industry

LONDON, March 3, 2023 /PRNewswire/ -- icometrix is proud to announce that, together with Queen Mary University of London (QMUL), it has been awarded the prestigious AI Award in Health and Care. This collaborative program will investigate the impact of AI on the assessment of MRI and decision making in the context of multi-disciplinary team meetings for people with MS. It is hoped that this research will lead to better care for people with MS (pwMS).

Key Points: 
  • The programme called AssistMS, is a collaboration between icometrix, QMUL, the University of Nottingham, and Barts Health and Nottingham University Hospitals Trusts.
  • The project is further supported by the East Midlands Imaging Network (EMRAD), InHealth Group and the MS Society of Great Britain & Northern Ireland.
  • pwMS receiving disease-modifying treatments (DMT) undergo annual MRI of the central nervous system to monitor disease activity.
  • Our joint efforts will undoubtedly transform care and improve outcomes for many PwMS for the better across Europe and beyond."